We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GENZYME-ILEX MERGER GETS CONDITIONAL OK FROM FTC
GENZYME-ILEX MERGER GETS CONDITIONAL OK FROM FTC
December 21, 2004
The FTC will allow biotechnology company Genzyme’s proposed $1 billion acquisition of Ilex Oncology to proceed as long as the companies surrender the rights to a key organ transplant drug, according to the terms of a consent order.